Search results for "Acute"

showing 10 items of 2516 documents

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.

2017

Several novel single nucleotide polymorphisms (SNPs) involved in cytarabine cytotoxicity and related to clinical outcomes have been reported recently in a series of 232 pediatric patients with acute myeloid leukemia (AML). We report the first adult AML cohort in which the influence of these SNPs in cytarabine efficacy and toxicity was analyzed. Six of polymorphisms with clinical significance in the previous study [rs12036333, rs10758713, rs9883101, rs6550826, IRX2: rs2897047, mutated in colorectal cancers (MCC): rs7729269] were analyzed in a cohort of 225 adult patients at initial diagnosis of AML treated with an induction scheme of idarubicin plus cytarabine. The variant alleles of rs12036…

0301 basic medicineOncologyAdultmedicine.medical_specialtyAdolescentPopulationSingle-nucleotide polymorphismKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineGeneticsmedicineIdarubicinHumansGeneral Pharmacology Toxicology and PharmaceuticseducationProspective cohort studyMolecular BiologyGenetics (clinical)Agededucation.field_of_studybusiness.industryCytarabineInduction chemotherapyMyeloid leukemiaInduction ChemotherapyMiddle AgedMinor allele frequencyLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisCytarabineMolecular Medicinebusinessmedicine.drugPharmacogenetics and genomics
researchProduct

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

2018

© 2018 by the authors.

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNPM1PTK2acute myeloid leukemialcsh:RC254-282Article03 medical and health sciences0302 clinical medicinePTK2BLYNInternal medicinehemic and lymphatic diseasesmedicineLYNprognostic factorPrognostic factorintermediate-riskPTK2BAcute myeloid leukemiaPTK2business.industryMyeloid leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCohortIntermediate-riskbusinessTyrosine kinaseProto-oncogene tyrosine-protein kinase SrcCancers
researchProduct

Expression profiles of HMGB1 on B-CLL related leukocytes contribute to prediction of relapse.

2020

The High Mobility Group Box 1 (HMGB1) is a nuclear protein that is frequently overexpressed in hematologic diseases and might be of relevance in immunogenic cancer control thus correlating with patients' (pts.) prognosis in diseases such as acute myeloid, acute lymphatic and chronic lymphocytic leukemia.Expression profiles of blasts from AML (n = 21), ALL (n = 16) and of B-lymphocytes of CLL (n = 9) pts. were analyzed for surface expression of HMGB1 using flow cytometry. Expression was quantified and correlated with clinically and prognostically relevant markers.Expression profiling of HMGB1 in blasts of AML and ALL subtypes did not show differences between primary vs. secondary disease dev…

0301 basic medicineOncologyMalemedicine.medical_specialtyMyeloidChronic lymphocytic leukemiaImmunologyPlasma Cellschemical and pharmacologic phenomenaHMGB1Biomarkers PharmacologicalFlow cytometryDiagnosis Differential03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineImmunology and AllergyHumansAnthracyclinesNuclear proteinHMGB1 ProteinB-LymphocytesAntibiotics Antineoplasticbiologymedicine.diagnostic_testbusiness.industryRemission InductionAge FactorsHematologyMiddle AgedGender relatedmedicine.diseaseFlow CytometryPrognosisLeukemia Lymphocytic Chronic B-CellGene expression profilingGene Expression Regulation NeoplasticLeukemia Myeloid Acute030104 developmental biologyLymphatic systemmedicine.anatomical_structurebiology.proteinDisease ProgressionFemaleNeoplasm Recurrence Localbusiness030215 immunologyImmunobiology
researchProduct

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

2015

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

0301 basic medicineOncologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BPolymorphism Single Nucleotide03 medical and health sciencesRemission induction0302 clinical medicinehemic and lymphatic diseasesInternal medicinemental disordersGeneticsOverall survivalHumansMedicineSurvival ratePharmacologybusiness.industryRemission InductionComplete remissionMyeloid leukemiaSurvival RateLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisMeta-analysisMolecular MedicinebusinessThe Pharmacogenomics Journal
researchProduct

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After All…

2020

Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the C…

0301 basic medicineOncologymedicine.medical_specialtyCancer Researchmedicine.medical_treatmentT lymphocytesCase ReportHematopoietic stem cell transplantationlcsh:RC254-282Donor lymphocyte infusionbone marrow microenviroment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineacute lymhoblastic leukemiaInternal medicinehemic and lymphatic diseasesT lymphocytemedicineponatinibbusiness.industryPonatinibDonor Lymphocyteslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDasatinib030104 developmental biologymedicine.anatomical_structurechemistryOncology030220 oncology & carcinogenesisdonor lymphocyte infusion (DLI)Bone marrowStem cellbusinessCD8medicine.drugFrontiers in Oncology
researchProduct

Pharmacogenomics and the treatment of acute myeloid leukemia.

2016

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding transporters, metabolizers or molecular targets of chemotherapy agents. A systematic review on all eligible studies was carried out in order to estimate the effect of polymorphisms of anthracyclines and cytarabine pathways on efficacy and toxicity of AML treatment. Other emerging gene…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBiologyMalignancy03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineSNPHumansGenetic variabilityPharmacologyChemotherapyPolymorphism GeneticMyeloid leukemiamedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyPharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsImmunologyCytarabineMolecular MedicinePharmacogeneticsmedicine.drugPharmacogenomics
researchProduct

Non-invasive Biomarkers of Acute Rejection in Kidney Transplantation: Novel Targets and Strategies

2019

Abstract: Kidney transplantation is considered the favored treatment for patients suffering from end-stage renal disease, since successful transplantation is associated with longer survival and improved quality of life compared to dialysis. Alloreactive immune responses against the donor kidney may lead to acute rejection of the transplant. The current diagnosis of renal allograft rejection mainly relies on clinical monitoring, including serum creatinine, proteinuria, and confirmation by histopathologic assessment in the kidney transplant biopsy. These parameters have their limitations. Identification and validation of biomarkers, which correlate with or predict the presence of acute reject…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentMini Reviewnon-invasivekidney transplantationDisease030230 surgeryacute rejectioncell-free DNA03 medical and health scienceschemistry.chemical_compoundtranscriptomics0302 clinical medicineproteomicsInternal medicineBiopsymedicineDialysisKidney transplantationlcsh:R5-920CreatinineProteinuriamedicine.diagnostic_testbusiness.industrytransplant outcomeGeneral Medicinemedicine.diseaseTransplantation030104 developmental biologysurgical procedures operativechemistryBiomarker (medicine)MedicinebiomarkerHuman medicinemedicine.symptomlcsh:Medicine (General)business
researchProduct

Potential Influence of Helminth Molecules on COVID-19 Pathology

2020

In recent months, the parasitology research community has been tasked with investigation of the influence of parasite coinfection on coronavirus disease 2019 (COVID-19) outcomes. Herein, we share our approach to analyze the effect of the trematode Fasciola hepatica as a modulator of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and of COVID-19 pathology.

0301 basic medicinePathologymedicine.medical_specialtyFascioliasisCoronavirus disease 2019 (COVID-19)Helminth proteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)viruses030231 tropical medicineInfection modulation03 medical and health sciences0302 clinical medicineAntigenic ModulationPathology modulationparasitic diseasesMedicineParasite hostingFasciola hepaticaHelminthsAnimalsHumansImmunologic FactorsInflammationHelminth parasitesRespiratory Distress SyndromebiologyForumbusiness.industryCoinfectionvirus diseasesCOVID-19Helminth ProteinsFasciola hepaticamedicine.diseasebiology.organism_classificationImmunity Innate030104 developmental biologyInfectious DiseasesParasitologyCoinfectionParasitologybusinessTrends in Parasitology
researchProduct

Acute onset of bulbar amyotrophic lateral sclerosis after flu – look at the differential diagnosis: A case report

2018

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting upper and lower motor neurones. It can be either familial (fALS) or sporadic (sALS). ALS is characterized by muscle weakness and atrophy that can involve the limbs and trunk (i.e. the spinal form of the disease) or speech and swallowing (i.e. the bulbar form). The aetiology of sALS remains unclear although a gene–environment interaction has been proposed as a concomitant trigger for the neurodegenerative process together with viral infections, smoking, heavy metals and pesticide exposure. Herein, we report the case of a 67-year-old woman who experienced an acute onset of bulbar ALS with an atypical clinical cours…

0301 basic medicinePathologymedicine.medical_specialtyMedicine (General)DiseaseCase Reportsacute onsetBiochemistryDiagnosis Differential03 medical and health sciences0302 clinical medicineAtrophyR5-920Swallowingsporadic amyotrophic lateral sclerosisDiagnosisdifferential diagnosisInfluenza HumanMedicineHumansAmyotrophic lateral sclerosisAgedbulbar amyotrophic lateral sclerosisbusiness.industryBiochemistry (medical)Amyotrophic Lateral SclerosisMuscle weaknessCell BiologyGeneral Medicinemedicine.diseaseTrunkInfluenza030104 developmental biologyDifferentialAcute DiseaseEtiologyFamilial amyotrophic lateral sclerosisFemaleacute onset; bulbar amyotrophic lateral sclerosis; differential diagnosis; Familial amyotrophic lateral sclerosis; sporadic amyotrophic lateral sclerosis; Acute Disease; Aged; Amyotrophic Lateral Sclerosis; Diagnosis Differential; Female; Humans; Influenza HumanDifferential diagnosismedicine.symptombusiness030217 neurology & neurosurgeryHumanJournal of International Medical Research
researchProduct

Posterior reversible encephalopathy syndrome revealing acute intermittent porphyria

2016

0301 basic medicinePathologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryPosterior reversible encephalopathy syndromeMagnetic resonance imaging030105 genetics & hereditymedicine.disease03 medical and health sciences0302 clinical medicinePorphyriaNeurologyPosterior Leukoencephalopathy SyndromemedicineNeurology (clinical)Differential diagnosisbusiness030217 neurology & neurosurgeryAcute intermittent porphyriaRevue Neurologique
researchProduct